See more : Schulz S.A. (SHUL3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of OrganiGram Holdings Inc. (OGI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OrganiGram Holdings Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hana Microelectronics Public Company Limited (HAA1.F) Income Statement Analysis – Financial Results
- Abri SPAC I, Inc. (ASPAU) Income Statement Analysis – Financial Results
- Takashimaya Company, Limited (TKSHF) Income Statement Analysis – Financial Results
- Century Sage Scientific Holdings Limited (1450.HK) Income Statement Analysis – Financial Results
- Fujian Start Group Co.Ltd (600734.SS) Income Statement Analysis – Financial Results
OrganiGram Holdings Inc. (OGI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.organigram.ca
About OrganiGram Holdings Inc.
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 159.84M | 149.21M | 145.81M | 79.16M | 86.80M | 80.41M | 12.43M | 5.71M | 6.13M | 986.68K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.32M | 114.13M | 114.24M | 107.56M | 143.29M | 31.94M | 39.20M | 8.84M | 813.38K | 339.51K | 274.91K | 0.00 | 0.00 |
| Gross Profit | 47.52M | 35.07M | 31.57M | -28.40M | -56.49M | 48.47M | -26.78M | -3.13M | 5.31M | 647.17K | -274.91K | 0.00 | 0.00 |
| Gross Profit Ratio | 29.73% | 23.51% | 21.65% | -35.87% | -65.08% | 60.28% | -215.42% | -54.73% | 86.73% | 65.59% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.20M | 12.19M | 5.96M | 3.45M | 1.27M | 409.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 48.29M | 48.95M | 42.35M | 30.72M | 29.94M | 26.67M | 9.27M | 4.78M | 2.31M | 1.76M | 66.77K | 318.91K | 140.16K |
| Selling & Marketing | 19.85M | 17.86M | 16.86M | 15.81M | 16.53M | 14.63M | 6.30M | 2.85M | 1.76M | 720.97K | 181.44K | 0.00 | 0.00 |
| SG&A | 68.14M | 71.68M | 59.21M | 46.52M | 46.47M | 41.30M | 15.57M | 7.62M | 4.07M | 2.49M | 66.77K | 318.91K | 140.16K |
| Other Expenses | 3.85M | 0.00 | 5.15M | -5.53M | -6.37M | 664.00K | 509.00K | 416.36K | 0.00 | 0.00 | 0.00 | 56.33K | 0.00 |
| Operating Expenses | 83.20M | 271.48M | 70.32M | 44.44M | 41.37M | 42.37M | 16.08M | 8.04M | 4.07M | 2.49M | 66.77K | 375.25K | 140.16K |
| Cost & Expenses | 195.51M | 385.61M | 184.56M | 152.00M | 184.65M | 74.31M | -23.99M | 16.88M | 4.88M | 2.15M | 66.77K | 375.25K | 140.16K |
| Interest Income | 0.00 | 3.69M | 1.49M | 854.00K | 308.00K | 662.00K | 0.00 | 9.87K | 0.00 | 0.00 | 996.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 277.85K | 429.00K | 2.96M | 6.01M | 9.67M | 10.09M | 273.87K | 436.37K | 115.41K | 996.00 | 0.00 | -140.16K |
| Depreciation & Amortization | 12.08M | 23.42M | 24.91M | 31.03M | 17.96M | 8.90M | 3.53M | 1.56M | 785.59K | 414.80K | 173.53K | 0.00 | 0.00 |
| EBITDA | -23.59M | -25.37M | -15.21M | -42.92M | -122.66M | 12.70M | 41.40M | -9.62M | 2.03M | -746.65K | 106.76K | -375.25K | -140.16K |
| EBITDA Ratio | -14.76% | -17.00% | -10.43% | -54.22% | -93.42% | 17.09% | 321.38% | -168.30% | 33.15% | -75.42% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.67M | -48.79M | -38.75M | -91.82M | -145.51M | 5.49M | 36.42M | -11.17M | 1.25M | -1.16M | -66.77K | -375.25K | -140.16K |
| Operating Income Ratio | -22.32% | -32.70% | -26.58% | -115.99% | -167.65% | 6.82% | 292.99% | -195.44% | 20.33% | -117.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.77M | -184.21M | 24.38M | -38.88M | -46.98M | -11.36M | -8.64M | 211.32K | -398.97K | -117.90K | 1.38M | 0.00 | 0.00 |
| Income Before Tax | -45.44M | -233.00M | -14.37M | -130.70M | -146.63M | -5.88M | 27.78M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | 0.00 |
| Income Before Tax Ratio | -28.43% | -156.16% | -9.86% | -165.11% | -168.94% | -7.31% | 223.49% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.52M | -88.00K | 1.84M | -10.47M | 3.63M | 5.65M | -550.94K | -37.41K | 2.49K | 171.54K | 0.00 | 140.16K |
| Net Income | -45.44M | -229.48M | -14.28M | -132.55M | -136.16M | -9.50M | 20.51M | -10.89M | 846.66K | -1.28M | -239.31K | -375.25K | -140.16K |
| Net Income Ratio | -28.43% | -153.80% | -9.80% | -167.43% | -156.87% | -11.82% | 165.04% | -190.59% | 13.82% | -129.41% | 0.00% | 0.00% | 0.00% |
| EPS | -0.44 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.68 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| EPS Diluted | -0.42 | -2.82 | -0.18 | -2.07 | -3.15 | -0.27 | 0.65 | -0.45 | 0.06 | -0.10 | -0.12 | -0.18 | -0.08 |
| Weighted Avg Shares Out | 103.80M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 30.14M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
| Weighted Avg Shares Out (Dil) | 108.38M | 81.29M | 77.23M | 64.03M | 43.17M | 35.23M | 31.72M | 24.30M | 14.67M | 13.10M | 2.07M | 2.07M | 1.75M |
Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold)
Organigram reported improved 3Q 2024 results. The company holds lead position in the Canadian cannabis market and is increasing its international cannabis exports. OGI stock price trades below its NAV per share and is undervalued.
Why Is Organigram (OGI) Stock Up 25% Today?
Organigram (NASDAQ: OGI ) stock is rising higher on Tuesday after the Canadian cannabis company released its most recent earnings report. The big news here is the company reporting C$41.06 million in revenue for its fiscal third quarter of the...
Organigram Holdings Inc. (OGI) Q3 2024 Earnings Call Transcript
Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Max Schwartz - Director of Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants...
Organigram's stock rises as Canadian pot company's revenue tops analyst estimate
OrganiGram Holdings Inc.'s stock OGI, -2.04% was up 4% in premarket trading Wednesday after the Canadian cannabis producer reported beter-than-expected revenue. OrganiGram swung to third-quarter net income of C$2.82 million ($2.05 million), from a loss of C$213.45 million in the...
Organigram Reports Third Quarter Fiscal 2024 Results
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 (“Q3 Fiscal 2024”). THIRD QUARTER HIGHLIGHTS Third quarter net revenue increased...
Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June...
The 3 Best Cannabis Stocks to Buy in August 2024
Cannabis stocks initially sounded like a compelling opportunity when Canada became the first G7 nation to legalize recreational marijuana. At the time, the popular belief was that the U.S. would eventually follow suit.
3 Canadian Marijuana Stocks For Your August Watchlist
Investing in top marijuana stocks in 2024 can be a bit of a challenge. Sometimes it can be tough knowing which companies to consider and when to take action. For many no matter the sector investing is a skill that...
A $2 Billion Opportunity In Cannabis: How A Tobacco Giant Is Helping Organigram Seize The German Market
On July 10, Zuanic & Associates hosted a panel discussion focusing on the European cannabis market, featuring Benna Goldenberg, CEO of Organigram Holdings OGI, and Finn Age Hansel, CEO of Sanity Group.
Organigram Invests in Sanity Group, a Leading German Cannabis Company
TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from...
Source: https://incomestatements.info
Category: Stock Reports